Education
About Us
Working with TipRanks
Follow Us
RenovoRx (RNXT)
NASDAQ:RNXT
RNXT Stock Chart & Stats
$0.96
-$0.05(-3.65%)
At close: 4:00 PM EST
$0.96
-$0.05(-3.65%)
Day’s Range― - ―
52-Week Range$0.70 - $1.50
Previous CloseN/A
Volume39.72K
Average Volume (3M)288.82K
Market Cap
$35.35M
Enterprise Value$25.04M
Total Cash (Recent Filing)$10.04M
Total Debt (Recent Filing)$236.00K
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Apr 01, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding36,649,918
10 Day Avg. Volume236,040
30 Day Avg. Volume288,821
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)6.80
Price to Sales (P/S)708.18
P/FCF Ratio-3.33
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue26.99
Enterprise Value/Gross Profit39.81
Enterprise Value/Ebitda-3.13
Forecast
1Y Price Target
$6.10Price Target Upside535.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressIndependent data monitoring committee recommended continuation of the pivotal Phase 3 TIGeR-PaC study after a pre-planned interim review, with enrollment on track to complete in early 2026 and final results expected in 2027, offering a major clinical catalyst if outcomes are favorable.
Commercialization And Market ExpansionDirect commercialization of the standalone RenovoCath, together with recent sales hires, growing numbers of approved treatment centers, and physician interest in additional solid tumor indications, could raise awareness, broaden applications, and support revenue growth toward profitability.
Product And Technology AdvantageThe FDA-cleared RenovoCath dual-balloon catheter employs trans-arterial micro-perfusion to improve delivery of anti-cancer drugs to tumors with poor blood supply, which could enhance effectiveness and tolerability compared with standard intravenous chemotherapy.
Bears Say
RenovoRx News
RNXT FAQ
What was RenovoRx’s price range in the past 12 months?
RenovoRx lowest stock price was $0.70 and its highest was $1.50 in the past 12 months.
What is RenovoRx’s market cap?
RenovoRx’s market cap is $35.35M.
When is RenovoRx’s upcoming earnings report date?
RenovoRx’s upcoming earnings report date is Apr 01, 2026 which is in 54 days.
How were RenovoRx’s earnings last quarter?
RenovoRx released its earnings results on Nov 13, 2025. The company reported -$0.08 earnings per share for the quarter, the consensus estimate of -$0.08 by $0.
Is RenovoRx overvalued?
According to Wall Street analysts RenovoRx’s price is currently Undervalued.
Does RenovoRx pay dividends?
RenovoRx does not currently pay dividends.
What is RenovoRx’s EPS estimate?
RenovoRx’s EPS estimate is -0.08.
How many shares outstanding does RenovoRx have?
RenovoRx has 36,649,918 shares outstanding.
What happened to RenovoRx’s price movement after its last earnings report?
RenovoRx reported an EPS of -$0.08 in its last earnings report, expectations of -$0.08. Following the earnings report the stock price went down -22.998%.
Which hedge fund is a major shareholder of RenovoRx?
Currently, no hedge funds are holding shares in RNXT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RenovoRx Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.10 (535.42% Upside)
$6.10 (535.42% Upside)
Insider Transactions
Bought Shares
Worth $64.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days <0.1%
Last 30 Days ▲ 14.2%
Last 30 Days ▲ 14.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.27%
12-Months-Change
Fundamentals
Return on Equity
-146.61%
Trailing 12-Months
Asset Growth
11.71%
Trailing 12-Months
Company Description
RenovoRx
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
RNXT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
RenovoRx's earnings call highlights a strong commercial momentum with the expansion of their TAMP therapy and RenovoCath device, coupled with solid financial health and promising clinical trial progress. Despite being in the early stages of commercialization and facing a long sales cycle, the overall sentiment is positive due to the significant advancements and strategic positioning for future growth.View all RNXT earnings summariesRNXT Stock 12 Month Forecast
Average Price Target
$6.10
▲(535.42% Upside)
Technical Analysis
Ovid Therapeutics
―
Grace Therapeutics
―
Jasper Therapeutics
―
Neurosense Therapeutics Ltd.
―
PepGen Inc.
―
Ownership Overview
3.52% Insiders
4.95% Mutual Funds
0.05% Other Institutional Investors
87.62% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---